Latest Insulin therapy Stories

The world diabetes care devices market was worth USD 16.2 billion last year and is forecast to grow at a CAGR of 6% to reach USD 24.3 billion in 2017. New market research report “Asia-Pacific Diabetes Care Devices Market Outlook to 2017 - Glucose Monitoring and Insulin Delivery” developed by GlobalData has been recently published by Market Publishers Ltd. London, UK (PRWEB) December 28, 2011 The world diabetes care devices market was worth USD 16.2 billion last year and is forecast to...

FARMINGTON, Conn., Dec. 1, 2011 /PRNewswire-iReach/ -- Global Information, Inc. (GII) presents Insulin Pumps - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 by GlobalData. (Photo: http://photos.prnewswire.com/prnh/20111201/CG15956) Insulin pump are small computer-driven mechanical devices that deliver insulin in a precisely controlled manner at pre-programmed intervals, and are extremely helpful to diabetic patients who need several daily injections of...

INDIANAPOLIS, Dec. 1, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals. <font size="2" face="Arial">(Logo: http://photos.prnewswire.com/prnh/20111111/DE03493LOGO )</font> Many people with diabetes who take daily...

SIOUX FALLS, S.D., Nov. 17, 2011 /PRNewswire-iReach/ -- A South Dakota pharmaceutical company, pharmaCline((TM)), is doing its part for National Diabetes Month by launching a new antibiotic called Diabecline(®) to help diabetic patients with foot problems. Diabetes affects at least 25 million citizens in the United States, in addition to 79 million Americans who are pre-diabetic. (Photo: <font size="2"...

SAN DIEGO, Nov. 16, 2011 /PRNewswire/ -- Tandem Diabetes Care, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the Company clearance to market the t:slim(TM) Insulin Delivery System (t:slim). This new full-featured pump is the first-ever with a color touch screen, and is the smallest insulin pump system currently available. The t:slim is one of the first insulin pumps to be cleared under the FDA's new Infusion Pump Improvement Initiative. "With the...

PRINCETON, N.J. and INDIANAPOLIS, Ind., Nov. 15, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams, Inc. announced today that the two organizations have entered into a multi-year extension of their partnership. Novo Nordisk will remain the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. To view the multimedia assets associated with this release, please click:...

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from a study in patients with type 1 diabetes that receive their insulin therapy via pumps. The Phase 1b study was conducted as a randomized, double-blind, crossover design, to determine insulin...

SAN DIEGO, Oct. 21, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from two Phase 2 clinical trials of its ultrafast PH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to the...

(Ivanhoe Newswire) -- There are some genes we wish would not fit.  Ten years of mouse breeding, screening, and record-keeping have finally paid off for Alan Attie and his lab members.  A recent study has pinpointed a gene that gives diabetes susceptibility in obese mice. They also showed that the protein coded by the gene, called tomosyn-2, acts as a brake on insulin secretion from the pancreas. "It's too early for us to know how relevant this gene will be to human diabetes," Attie, a...

The number of individuals with type 2 diabetes is reaching epidemic proportions. One of the main risk factors for developing type 2 diabetes is resistance of cells in the body (particularly liver, fat, and skeletal muscle cells) to the effects of the hormone insulin. Substantially reducing caloric intake enhances the sensitivity of skeletal muscle to insulin. Defining the molecular signals within skeletal muscle linking caloric restriction to improved insulin action could provide new targets...